Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

538 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.
Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A. Goel S, et al. Among authors: maciejewski jp. Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. Leukemia. 2016. PMID: 27125205 No abstract available.
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP. Jiang Y, et al. Among authors: maciejewski jp. Blood. 2009 Feb 5;113(6):1315-25. doi: 10.1182/blood-2008-06-163246. Epub 2008 Oct 2. Blood. 2009. PMID: 18832655 Free PMC article.
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.
Szpurka H, Jankowska AM, Makishima H, Bodo J, Bejanyan N, Hsi ED, Sekeres MA, Maciejewski JP. Szpurka H, et al. Among authors: maciejewski jp. Leuk Res. 2010 Aug;34(8):969-73. doi: 10.1016/j.leukres.2010.02.033. Epub 2010 Mar 23. Leuk Res. 2010. PMID: 20334914 Free PMC article.
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Advani AS, Tiu R, Saunthararajah Y, Maciejewski J, Copelan EA, Sobecks R, Sekeres MA, Bates J, Rush ML, Tripp B, Salvado A, Noon E, Howard M, Jin T, Hsi E, Egorin MJ, Lim K, Cotta CV, Price C, Kalaycio M. Advani AS, et al. Leuk Res. 2010 Dec;34(12):1622-6. doi: 10.1016/j.leukres.2010.03.021. Epub 2010 Apr 27. Leuk Res. 2010. PMID: 20427086 Clinical Trial.
538 results